tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Latest News

Nuvilex, Inc. Shows Success Treating Mammary Tumors Using Cell Encapsulation Technology

Nuvilex, Inc. Shows Success Treating Mammary Tumors Using Cell Encapsulation Technology

Written by ι Stock Market Media Group Staff — May 7, 2013

Nuvilex, Inc. (OTCQB: NVLX) should be convincing investors by now that its technology could truly change the face of healthcare.  Many know of the company’s “Cell-in-a-Box” technology for its performance in clinical trials for advanced, inoperable pancreatic cancer, and its performance in pre-clinical studies for diabetes where it essentially created a type of “artificial pancreas.”  But, the company isn’t stopping there when it comes to showing the technology’s flexibility.

“Cell-in-a-Box” or living cell encapsulation has also been involved in treating mammary tumors in dogs.  Mammary tumors in dogs are a “model system” that can be used to mimic breast cancer in humans.  Clearly the company is demonstrating that it can encapsulate any type of living cell for use in the human body, and once transplanted into a patient, those cells will go to work to treat the disease or problem they’re designed to treat. 

In the study to treat mammary tumors in dogs, as in the human pancreatic cancer studies, it emphasizes again that cell encapsulation can be used as a “targeting” device for the treatment of “solid” tumors.  In the pancreatic cancer studies, Nuvilex’s cell encapsulation was combined with the cancer killing drug ifosfamide; however, in the mammary tumors study, cyclophosphamide (Cytoxan) was used instead because cyclophosphamide is often used by veterinarians to treat canine mammary cancer and by oncologists to treat breast cancer in humans. 

The same type of drug-activating cells was encapsulated in the study as the company used for the pancreatic cancer studies because the same enzyme within those cells can activate both ifosfamide and cyclophosphamide.  In the dog studies, encapsulated cells were injected into the mammary tumors and then followed by four treatments with cyclophosphamide.  These four treatments came 2, 9, 22, and 29 days after the encapsulated cells were injected.  Cyclophosphamide was used in the study at its standard dose, and it was given using its standard route of administration.

Dogs receiving the cell encapsulation/cyclophosphamide treatment exhibited a statistically greater degree of tumor shrinkage than those dogs that received the cyclophosphamide alone.  Interestingly, one of the dogs in the study had two spontaneous tumors.  One tumor was treated with cell encapsulation/cyclophosphamide and the other tumor was treated with cyclophosphamide alone allowing the company to directly compare the effects of adding encapsulated drug-activating cells to systemic cyclophosphamide to those of systemic cyclophosphamide alone in the same animal.

Once again the technology performed amazingly as the tumor receiving the cell encapsulation/cyclophosphamide treatment shrank in size by an eye-popping 70% compared to only 14% for the tumor not receiving the encapsulated cells and that was only treated with cyclophosphamide.  Additionally, before the study, the sizes of the tumors were measured and then each tumor was removed four weeks after the completion of the cyclophosphamide treatments.   Just as they were in the pancreatic cancer studies, the capsules containing the drug-activating cells were well tolerated and no “safety” issues were seen.

Now while this study was done several years ago, it again emphasizes that Nuvilex’s “Cell-in-a-Box” can be used as a “targeting” device for the treatment of “solid” tumors.  This study clearly demonstrated the beneficial effects of the tumor-localized encapsulated drug-activating cells. 

Nuvilex COO Dr. Gerald Crabtree said of the study:

“This study serves as further proof that our concept clearly works, and it could ultimately lead to our conducting human clinical trials, but it would have to be repeated to get additional data before such trials are conducted.”

The company has a technology that seems to see great data after each performance, and no matter the area of study, improvement is seen over the current standard.  So, this should be exciting news for the industry and should leave investors in this company with plenty of hope for a very strong future.